Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. 1996

M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
Cornell University Medical College, New York, New York, USA.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D053327 Apolipoprotein E4 A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES. Apo E epsilon 4,Apo E-4,Apo E4,ApoE4,Apolipoprotein E-4,Apo E 4,Apolipoprotein E 4

Related Publications

M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
April 2014, Neuroscience bulletin,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
December 2006, Proceedings of the National Academy of Sciences of the United States of America,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
March 1995, The Biochemical journal,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
September 2006, Fukuoka igaku zasshi = Hukuoka acta medica,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
January 2012, Alzheimer's research & therapy,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
January 2007, Journal of cellular and molecular medicine,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
April 1993, Biochemical and biophysical research communications,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
September 1995, American journal of public health,
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
April 2009, Drugs of today (Barcelona, Spain : 1998),
M Kaplitt, and G K Gouras, and H Makimura, and J Jovanovic, and D Sweeney, and P Greengard, and N R Relkin, and S Gandy
August 2005, Journal of Alzheimer's disease : JAD,
Copied contents to your clipboard!